Developing Innovative Treatments for Stroke and Other Vascular Diseases

Learn more about Diamedica

About Diamedica

DiaMedica (TSX-V:DMA) is a biopharmaceutical company focused on developing innovative treatments for stroke and other vascular diseases where no current therapies are available.

About Diamedica
Learn more about Diamedica

Product Pipeline

DiaMedica’s lead clinical stage product, DM199, is a recombinant human tissue kallikrien (rhKLK-1) protein to treat vascular and metabolic diseases.

Investors

Investors

-- DMA
-- TSX Venture Exchange
--
-- DMCAF
-- OTCQB
--
View Investor Relations ›